bioAffinity Technologies, Inc.: to present new data at CHEST 2026

What happened
On Oct 13, 2026, bioAffinity Technologies, Inc. issued a press release announcing that it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company’s sputum-based tests in development to characterize lung inflammation and detect multiple protein biomarkers of lung inflammation, including biologic drug targets of therapeutics used to treat asthma and chronic obstructive pulmonary disease (COPD). The filing states the sputum-based tests are investigational, have not been validated, are not cleared or approved by the U.S. Food and Drug Administration, and are not currently available for clinical or diagnostic use. A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference.

Key details

• Date filed: Oct 13, 2026.
• Event: presentation of new data at CHEST 2026 (annual meeting of the American College of Chest Physicians).
• Subject: sputum-based tests in development to characterize lung inflammation and detect multiple protein biomarkers, including biologic drug targets for asthma and COPD.
• Regulatory status: tests are investigational, not validated, not cleared or approved by the U.S. Food and Drug Administration, and not available for clinical or diagnostic use.

Why it may matter
The filing reports Item 8.01 (Other events), covering the Company’s issuance of a press release about a planned presentation of data on investigational sputum-based tests at CHEST 2026. A filing does not show why the insider traded or why the company acted.